adenine has been researched along with Liver Cirrhosis in 136 studies
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients." | 9.22 | [Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016) |
| "To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course." | 9.20 | [A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015) |
| "To compare efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for hepatitis B virus (HBV)-related decompensated liver cirrhosis." | 9.17 | De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. ( Chen, JY; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2013) |
| "To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil." | 9.16 | [Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012) |
| "A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy." | 9.15 | Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011) |
| "This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months." | 9.15 | Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011) |
| "To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis." | 9.13 | [Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis]. ( Chen, YS; Jin, ZJ; Li, DF; Qiao, LM; Zhou, J, 2008) |
| "To evaluate the efficacy and safety of 48 weeks adefovir dipivoxil (ADV) treatment for chronic hepatitis patients with cirrhosis in their decompensation period." | 9.12 | [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]. ( Gong, ZJ; Hu, DF; Yang, Q, 2007) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued." | 9.12 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006) |
| "The purpose of this prospective study was to evaluate the efficacy and safety of adefovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resistant chronic hepatitis B patients." | 9.11 | Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. ( Choi, WB; Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Suh, DJ, 2005) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B." | 9.11 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005) |
| " Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | 9.10 | Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients." | 7.91 | Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019) |
| "This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients." | 7.80 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014) |
| "Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV)." | 7.80 | Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. ( Cho, M; Choi, JY; Han, KH; Hwang, JS; Kim, BI; Kim, DJ; Lee, CK; Lee, HJ; Paik, SW; Suh, DJ; Um, SH; Woo, HY; Yoon, SK, 2014) |
| "One advanced schistosomiasis patient with hepatitis B cirrhosis was treated with lamivudine and adefovir dipivoxil and the curative effect was satisfied." | 7.79 | [Treatment of one advanced schistosomiasis patient with hepatitis B cirrhosis by lamivudine and adefovir dipivoxil]. ( Li, YC, 2013) |
| "Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)." | 7.79 | Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013) |
| "Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited." | 7.75 | Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009) |
| "To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy." | 7.73 | [Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005) |
| "Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV)." | 7.73 | [Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease]. ( Choi, MS; Koh, KC; Lee, JH; Moon, W; Moon, YM; Paik, SW; Rhee, JC; Shim, SG; Yoo, BC, 2005) |
| "Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine-resistant mutants and worsening liver function, and to multifactorial nephrotoxicity." | 7.73 | Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. ( Cañas, C; Casais, LA; Casanova, A; Chahri, N; Figueras, J; Gornals, J; Lopez, C; Taltavull, TC; Verdura, B, 2005) |
| "Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile." | 7.72 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004) |
| " A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis." | 7.72 | Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003) |
| "In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores." | 5.24 | Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance. ( Chang, S; Chen, B; Qiu, L; Shen, F; Sun, Y; Wu, K; Yu, L, 2017) |
| "To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients." | 5.22 | [Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016) |
| "To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course." | 5.20 | [A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015) |
| "We examined the durability of the virological response after discontinuing lamivudine (LVD) in chronic hepatitis B (CHB) patients with LVD-resistant hepatitis B virus (HBV), who responded to LVD plus adefovir (ADV) combination therapy, and the outcome of switching to ADV monotherapy compared to maintaining combination therapy." | 5.19 | Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, HS; Kim, MN; Kim, SU; Lee, CK; Lee, S; Park, JY, 2014) |
| "This study assessed the clinical efficacy of lamivudine and adefovir dipivoxil combined with autologous bone marrow stem cell transplantation as treatment for patients with hepatitis B and decompensated liver cirrhosis." | 5.19 | Curative effect of combined lamivudine, adefovir dipivoxil, and stem cell transplantation on decompensated hepatitis B cirrhosis. ( He, CP; Huang, LW; Ling, K; Liu, L; Wang, XM; Wen, QM; Yan, Y; Zhou, HC; Zhou, J, 2014) |
| "To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients." | 5.17 | Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. ( Chen, Y; Li, LJ; Lv, GC; Sheng, JF; Yang, YD; Yao, JM; Zheng, L, 2013) |
| "To compare efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for hepatitis B virus (HBV)-related decompensated liver cirrhosis." | 5.17 | De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. ( Chen, JY; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2013) |
| "To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil." | 5.16 | [Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012) |
| "A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy." | 5.15 | Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011) |
| "This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months." | 5.15 | Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011) |
| "To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis." | 5.13 | [Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis]. ( Chen, YS; Jin, ZJ; Li, DF; Qiao, LM; Zhou, J, 2008) |
| "To evaluate the efficacy and safety of 48 weeks adefovir dipivoxil (ADV) treatment for chronic hepatitis patients with cirrhosis in their decompensation period." | 5.12 | [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]. ( Gong, ZJ; Hu, DF; Yang, Q, 2007) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued." | 5.12 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006) |
| "Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B." | 5.11 | Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005) |
| "The purpose of this prospective study was to evaluate the efficacy and safety of adefovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resistant chronic hepatitis B patients." | 5.11 | Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. ( Choi, WB; Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Suh, DJ, 2005) |
| " Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | 5.10 | Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates such as entecavir or tenofovir could suppress hepatitis B virus (HBV) replication, improve liver function, delay or obviate the need for liver transplantation in some patients, and reduce the risk of HBV recurrence." | 4.90 | Prevention of hepatitis B virus reinfection in liver transplant recipients. ( Roche, B; Samuel, D, 2014) |
| "Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure." | 4.84 | Review article: current antiviral therapy of chronic hepatitis B. ( Ayoub, WS; Keeffe, EB, 2008) |
| " Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)." | 4.82 | [Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003) |
| "To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients." | 3.91 | Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019) |
| " Drugs currently used against HBV include IFN-α that decreases viremia, inflammation and the growth of liver fibrosis, and adefovir that decreases the viral load." | 3.88 | Chronic hepatitis B virus and liver fibrosis: A mathematical model. ( Friedman, A; Siewe, N, 2018) |
| "None of the patients developed lactic acidosis during follow-up [median: 58 (6-155) months]." | 3.85 | Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. ( Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G, 2017) |
| "This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients." | 3.80 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014) |
| "Since the licensing of lamivudine in 1999, the treatment of chronic hepatitis B has been revolutionized by the introduction of oral nucleoside and nucleotide analogues (NAs), which act as inhibitors of the HBV polymerase." | 3.80 | Antiviral therapy of chronic hepatitis B. ( Berg, T; van Bömmel, F, 2014) |
| "Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV)." | 3.80 | Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. ( Cho, M; Choi, JY; Han, KH; Hwang, JS; Kim, BI; Kim, DJ; Lee, CK; Lee, HJ; Paik, SW; Suh, DJ; Um, SH; Woo, HY; Yoon, SK, 2014) |
| "Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)." | 3.79 | Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013) |
| " We investigated the long-term safety and efficacy of these antiviral drugs in patients with chronic hepatitis B virus (HBV) infection, with compensated or decompensated cirrhosis, and compared results with those from lamivudine." | 3.79 | Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. ( Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013) |
| "We studied the cost-effectiveness of tenofovir and entecavir in e antigen positive (CHBe+) and negative (CHBe-) chronic hepatitis B." | 3.79 | Should chronic hepatitis B be treated as early as possible? ( Colle, I; Gamil, M; Horsmans, Y; Hulstaert, F; Nevens, F; Schwierz, C; Thiry, N; Van de Sande, S, 2013) |
| "One advanced schistosomiasis patient with hepatitis B cirrhosis was treated with lamivudine and adefovir dipivoxil and the curative effect was satisfied." | 3.79 | [Treatment of one advanced schistosomiasis patient with hepatitis B cirrhosis by lamivudine and adefovir dipivoxil]. ( Li, YC, 2013) |
| "Before tenofovir approval for chronic hepatitis B therapy, the clinical management of patients with suboptimal response or virological breakthrough during combination treatment with lamivudine and adefovir dipivoxil was a difficult clinical challenge." | 3.78 | High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. ( Aldini, R; Azzaroli, F; Buonfiglioli, F; Galli, S; Giandinoto, M; Lisotti, A; Mazzella, G; Montagnani, M; Turco, L, 2012) |
| "Adefovir dipivoxil, an acyclic nucleoside analogue, has been approved for the treatment of patients with chronic hepatitis B." | 3.76 | [A case of osteomalacia related to adefovir in a patient with chronic hepatitis B]. ( Ahn, SY; Choe, WH; Choi, YH; Jang, YM; Kim, BK; Ko, SY; Kwon, SY; Lee, CH, 2010) |
| "Data on the efficacy of adefovir dipivoxil (ADV) in elderly and cirrhotic patients with lamivudine-resistant (LAM-R) chronic hepatitis B are scarce." | 3.75 | Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. ( Bailly, F; Beaugrand, M; Benhamou, Y; Marcellin, P; Maynard, M; Monchecourt, F; Parvaz, P; Trepo, C; Trylesinski, A; Zarski, JP; Zoulim, F, 2009) |
| "Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited." | 3.75 | Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009) |
| "Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine-resistant mutants and worsening liver function, and to multifactorial nephrotoxicity." | 3.73 | Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. ( Cañas, C; Casais, LA; Casanova, A; Chahri, N; Figueras, J; Gornals, J; Lopez, C; Taltavull, TC; Verdura, B, 2005) |
| "To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy." | 3.73 | [Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005) |
| "Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV)." | 3.73 | [Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease]. ( Choi, MS; Koh, KC; Lee, JH; Moon, W; Moon, YM; Paik, SW; Rhee, JC; Shim, SG; Yoo, BC, 2005) |
| "Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile." | 3.72 | Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004) |
| "Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation." | 3.72 | Tenofovir therapy for lamivudine resistance following liver transplantation. ( Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG, 2004) |
| " A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis." | 3.72 | Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003) |
| "Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase." | 2.84 | Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial. ( Guo, H; Jiao, J; Liu, Z; Qi, W; Wang, J; Wang, X; Xu, Y; Yu, F; Zhao, P; Zhou, C, 2017) |
| "Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection." | 2.80 | Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. ( Bozkaya, H; Dalekos, GN; Deda, X; Gürel, S; Heidrich, B; Idilman, R; Keskin, O; Manns, M; Pehlivan, S; Tabak, F; Tüzün, A; Wedemeyer, H; Yalçın, K; Yurdaydin, C; Zachou, K; Zeuzem, S, 2015) |
| "Patients with chronic hepatitis B (HBeAg+ and HBeAg-) randomized in two trials of adefovir (ADV) vs placebo, with available paired liver biopsies and FT-AT at baseline and after 48 weeks of treatment were included." | 2.74 | Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. ( Benhamou, Y; Hadziyannis, S; Marcellin, P; Ngo, Y; Poynard, T; Ratziu, V, 2009) |
| "The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear." | 2.73 | Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. ( Brechot, C; Castaing, D; Dussaix, E; Fallot, G; Faria, LC; Ferrari, TC; Gigou, M; Guettier, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M, 2008) |
| "For chronic HBV carrier liver cirrhosis patients, a successful vaccine response can only be achieved in selected patients, such as those treated with experimentally reduced immunosuppression protocols." | 2.52 | Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. ( Takaki, A; Yagi, T; Yasunaka, T, 2015) |
| "Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0." | 2.50 | Management of chronic hepatitis B in children: an unresolved issue. ( Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S, 2014) |
| "Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective." | 2.48 | New advances in chronic hepatitis B. ( Lee, WM; Tujios, SR, 2012) |
| "Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent." | 2.48 | Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. ( Naggie, S; Sulkowski, MS, 2012) |
| "The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma." | 2.44 | Treatment of chronic hepatitis B infection: an update of Swedish recommendations. ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008) |
| "In patients with liver cirrhosis (Child B and C) only nucleos(t)ides should be used." | 2.43 | [Therapy of hepatitis B virus infection]. ( Trautwein, C, 2006) |
| "Regardless of prophylaxis, the risk of recurrence is associated with pre-graft viral load." | 2.43 | [Liver transplantation for complications of hepatitis B]. ( Roche, B; Samuel, D, 2006) |
| "Lamivudine appears to be a safe and effective antiviral agent, which may improve or stabilize liver disease in selected patients with advanced cirrhosis and active HBV replication." | 2.42 | Management of patients with decompensated HBV cirrhosis. ( Fontana, RJ, 2003) |
| "However, the role of β-arrestins in liver fibrosis remains unknown." | 1.51 | β-Arrestin1 enhances liver fibrosis through autophagy-mediated Snail signaling. ( Huang, X; Jiang, J; Liu, H; Lu, Y; Tan, S; Wu, B; Xu, M, 2019) |
| "Mortality and complications including hepatocellular carcinoma are associated primarily with cirrhosis and age, but not with HBeAg status or viral load probably because modern therapies considerably reduce viral replication in almost all patients." | 1.43 | Long-term follow-up of HBsAg-positive patients in Germany. ( Amani, A; Niederau, C; Thiel, A, 2016) |
| "Liver fibrosis was measured using elastometry." | 1.40 | Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. ( Barreiro, P; Fernández-Montero, JV; Labarga, P; Mendoza, Cd; Sierra-Enguita, R; Soriano, V; Vispo, E, 2014) |
| "Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is the most frequent and difficult-to-treat viral hepatitis worldwide." | 1.39 | Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. ( Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F, 2013) |
| "Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce." | 1.36 | Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010) |
| " Mean HBIg half-life was 21." | 1.36 | Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ( Andreone, P; Bacci, M; Burra, P; Canova, D; Cursaro, C; Fiorentino, B; Guazzini, S; Marengo, A; Marzano, A; Riili, A; Volpes, R, 2010) |
| "Chronic hepatitis B affects 5-10% of HIV patients in Western countries." | 1.35 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009) |
| "A 36 year old man with chronic hepatitis B and cirrhosis was admitted in our Department for the onset of jaundice, ascites and ALT flare (x 35 u." | 1.35 | Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. ( Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (4.41) | 18.7374 |
| 1990's | 2 (1.47) | 18.2507 |
| 2000's | 54 (39.71) | 29.6817 |
| 2010's | 73 (53.68) | 24.3611 |
| 2020's | 1 (0.74) | 2.80 |
| Authors | Studies |
|---|---|
| Furukawa, S | 1 |
| Yamaguchi, M | 1 |
| Ooka, A | 1 |
| Kikuchi, H | 1 |
| Ishikawa, T | 1 |
| Saito, SY | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 7 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 5 |
| Wang, H | 5 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 3 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 4 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 6 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 5 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 5 |
| Liu, Z | 4 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 6 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 3 |
| Yang, Q | 3 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 3 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 4 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 2 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 2 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 10 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 3 |
| Huang, X | 3 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 3 |
| Li, J | 8 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 8 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 2 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 5 |
| Hu, T | 1 |
| Wang, F | 2 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 4 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 4 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 6 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 2 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 2 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 2 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 2 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 3 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 2 |
| Cui, Y | 1 |
| Zhang, L | 4 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 2 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 3 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 2 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 4 |
| Xue, H | 1 |
| Zhang, W | 2 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 2 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 3 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 2 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 2 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Hercun, J | 1 |
| Koh, C | 1 |
| Heller, T | 1 |
| Triantos, C | 1 |
| Kalafateli, M | 1 |
| Aggeletopoulou, I | 1 |
| Mandellou, M | 1 |
| Assimakopoulos, S | 1 |
| Tselekouni, P | 1 |
| Taprantzi, D | 1 |
| Tsiaoussis, G | 1 |
| Vourli, G | 1 |
| Anastassiou, ED | 1 |
| Gogos, C | 1 |
| Labropoulou-Karatza, C | 1 |
| Thomopoulos, K | 1 |
| Qi, W | 1 |
| Yu, F | 1 |
| Guo, H | 1 |
| Zhao, P | 1 |
| Wu, K | 1 |
| Shen, F | 1 |
| Qiu, L | 1 |
| Chen, B | 1 |
| Chang, S | 1 |
| Oh, H | 1 |
| Jun, DW | 1 |
| Kong, Y | 1 |
| Ma, H | 1 |
| You, H | 1 |
| Ou, X | 1 |
| Jia, J | 1 |
| Bai, F | 1 |
| Huang, Q | 1 |
| Nie, J | 1 |
| Lu, S | 1 |
| Lu, C | 1 |
| Zhuo, L | 1 |
| Lu, Z | 1 |
| Lin, X | 1 |
| Friedman, A | 1 |
| Siewe, N | 1 |
| Tan, S | 1 |
| Xu, M | 1 |
| Wu, B | 1 |
| Yan, JY | 1 |
| Li, ZQ | 1 |
| Yu, ZJ | 1 |
| Kan, QC | 1 |
| Li, T | 1 |
| Qu, Y | 1 |
| Lin, C | 1 |
| Yang, B | 1 |
| Sutherland, N | 1 |
| Li Wai Suen, CFD | 1 |
| Mills, C | 1 |
| Lokan, J | 1 |
| Sinclair, M | 1 |
| Tada, T | 1 |
| Toyoda, H | 1 |
| Yasuda, S | 1 |
| Miyake, N | 1 |
| Kumada, T | 1 |
| Kurisu, A | 1 |
| Ohisa, M | 1 |
| Akita, T | 1 |
| Tanaka, J | 1 |
| Iannazzo, S | 1 |
| Coco, B | 1 |
| Brunetto, MR | 1 |
| Rossetti, F | 1 |
| Caputo, A | 1 |
| Latour, A | 1 |
| Espinos, B | 1 |
| Bonino, F | 1 |
| Li, YC | 1 |
| Lv, GC | 1 |
| Yao, JM | 1 |
| Yang, YD | 2 |
| Zheng, L | 2 |
| Sheng, JF | 1 |
| Chen, Y | 2 |
| Li, LJ | 2 |
| Srivastava, M | 1 |
| Rungta, S | 1 |
| Dixit, VK | 1 |
| Shukla, SK | 1 |
| Singh, TB | 1 |
| Jain, AK | 1 |
| Peng, H | 1 |
| Tong, S | 1 |
| Yin, W | 1 |
| Hu, P | 1 |
| Lian, JS | 1 |
| Zeng, LY | 1 |
| Chen, JY | 1 |
| Jia, HY | 1 |
| Zhang, YM | 1 |
| Xiang, DR | 1 |
| Hu, JH | 1 |
| Lu, YF | 1 |
| Kim, JH | 2 |
| Ko, SY | 3 |
| Choe, WH | 3 |
| Kwon, SY | 3 |
| Lee, CH | 3 |
| Czech, B | 1 |
| Dettmer, K | 1 |
| Valletta, D | 1 |
| Saugspier, M | 1 |
| Koch, A | 1 |
| Stevens, AP | 1 |
| Thasler, WE | 1 |
| Müller, M | 1 |
| Oefner, PJ | 1 |
| Bosserhoff, AK | 1 |
| Hellerbrand, C | 1 |
| Kim, MN | 1 |
| Lee, CK | 2 |
| Ahn, SH | 2 |
| Lee, S | 1 |
| Kim, SU | 2 |
| Kim, DY | 2 |
| Kim, HS | 1 |
| Han, KH | 3 |
| Chon, CY | 1 |
| Park, JY | 2 |
| Calvaruso, V | 1 |
| Craxì, A | 2 |
| Triolo, M | 1 |
| Della Corte, C | 2 |
| Colombo, M | 4 |
| Price, J | 1 |
| Liu, L | 1 |
| Yan, Y | 1 |
| Zhou, J | 2 |
| Huang, LW | 1 |
| He, CP | 1 |
| Ling, K | 1 |
| Zhou, HC | 1 |
| Wen, QM | 1 |
| Wang, XM | 1 |
| Nobili, V | 1 |
| Comparcola, D | 1 |
| Cainelli, F | 1 |
| Vento, S | 1 |
| Cholongitas, E | 2 |
| Goulis, I | 2 |
| Antoniadis, N | 2 |
| Fouzas, I | 2 |
| Imvrios, G | 2 |
| Papanikolaou, V | 2 |
| Akriviadis, E | 2 |
| Woo, HY | 1 |
| Choi, JY | 1 |
| Yoon, SK | 1 |
| Suh, DJ | 2 |
| Paik, SW | 2 |
| Um, SH | 1 |
| Kim, BI | 1 |
| Lee, HJ | 2 |
| Cho, M | 1 |
| Kim, DJ | 1 |
| Hwang, JS | 1 |
| van Bömmel, F | 1 |
| Berg, T | 1 |
| Roche, B | 3 |
| Samuel, D | 4 |
| Soriano, V | 3 |
| Vispo, E | 3 |
| Sierra-Enguita, R | 1 |
| Mendoza, Cd | 1 |
| Fernández-Montero, JV | 1 |
| Labarga, P | 2 |
| Barreiro, P | 3 |
| Tsai, NC | 1 |
| Marcellin, P | 6 |
| Buti, M | 2 |
| Washington, MK | 1 |
| Lee, SS | 2 |
| Chan, S | 1 |
| Trinh, H | 1 |
| Flaherty, JF | 1 |
| Kitrinos, KM | 1 |
| Dinh, P | 1 |
| Charuworn, P | 1 |
| Subramanian, GM | 1 |
| Gane, E | 1 |
| Grizzi, F | 1 |
| Desmet, VJ | 1 |
| Coffin, CS | 1 |
| Rezaeeaval, M | 1 |
| Pang, JX | 1 |
| Alcantara, L | 1 |
| Klein, P | 1 |
| Burak, KW | 1 |
| Myers, RP | 1 |
| Ahn, SS | 1 |
| Chon, YE | 1 |
| Kim, BK | 3 |
| Gu, EL | 1 |
| Yu, YQ | 1 |
| Wang, JL | 1 |
| Ji, YY | 1 |
| Ma, XY | 1 |
| Xie, Q | 1 |
| Pan, HY | 1 |
| Wu, SM | 1 |
| Chen, CW | 1 |
| Xu, XW | 1 |
| Wang, YE | 1 |
| Yao, GB | 1 |
| Li, XY | 1 |
| You, X | 1 |
| Jie, YS | 1 |
| Lin, GL | 1 |
| Wu, YK | 1 |
| Huang, MX | 1 |
| Li, ZY | 1 |
| Xie, DY | 1 |
| Gao, ZL | 1 |
| Chong, YT | 1 |
| Keskin, O | 1 |
| Wedemeyer, H | 1 |
| Tüzün, A | 1 |
| Zachou, K | 1 |
| Deda, X | 1 |
| Dalekos, GN | 1 |
| Heidrich, B | 1 |
| Pehlivan, S | 1 |
| Zeuzem, S | 1 |
| Yalçın, K | 1 |
| Gürel, S | 1 |
| Tabak, F | 1 |
| Idilman, R | 1 |
| Bozkaya, H | 1 |
| Manns, M | 1 |
| Yurdaydin, C | 1 |
| Lampertico, P | 3 |
| Invernizzi, F | 1 |
| Viganò, M | 2 |
| Loglio, A | 1 |
| Mangia, G | 1 |
| Facchetti, F | 1 |
| Primignani, M | 1 |
| Jovani, M | 1 |
| Iavarone, M | 1 |
| Fraquelli, M | 1 |
| Casazza, G | 1 |
| de Franchis, R | 1 |
| Takaki, A | 1 |
| Yasunaka, T | 1 |
| Yagi, T | 1 |
| Niederau, C | 2 |
| Amani, A | 1 |
| Thiel, A | 1 |
| Lian, J | 1 |
| Han, T | 1 |
| Xiang, H | 1 |
| Liu, F | 1 |
| Lyu, H | 1 |
| Wang, GL | 1 |
| Qiu, P | 1 |
| Zhou, SF | 1 |
| Xu, LF | 1 |
| Wen, P | 1 |
| Wen, JB | 1 |
| Xiao, XZ | 1 |
| Duan, SH | 1 |
| Bao, ZY | 1 |
| Yuan, XD | 1 |
| Liu, MS | 1 |
| Giakoustidis, D | 1 |
| Giouleme, O | 1 |
| Vasiliadis, T | 1 |
| Shi, H | 2 |
| Ren, F | 1 |
| Duan, Z | 1 |
| Murata, K | 1 |
| Asano, M | 1 |
| Matsumoto, A | 1 |
| Sugiyama, M | 1 |
| Nishida, N | 1 |
| Tanaka, E | 1 |
| Inoue, T | 1 |
| Sakamoto, M | 1 |
| Enomoto, N | 1 |
| Shirasaki, T | 1 |
| Honda, M | 1 |
| Kaneko, S | 1 |
| Gatanaga, H | 1 |
| Oka, S | 1 |
| Kawamura, YI | 1 |
| Dohi, T | 1 |
| Shuno, Y | 1 |
| Yano, H | 1 |
| Mizokami, M | 1 |
| Ying, H | 1 |
| Wei, L | 1 |
| Hong, LJ | 1 |
| Chung, GE | 1 |
| Cho, EJ | 1 |
| Yoo, JJ | 1 |
| Lee, M | 1 |
| Cho, Y | 1 |
| Lee, DH | 1 |
| Kim, HY | 1 |
| Yu, SJ | 1 |
| Kim, YJ | 1 |
| Yoon, JH | 1 |
| Zoulim, F | 2 |
| Li, DF | 1 |
| Jin, ZJ | 1 |
| Chen, YS | 1 |
| Qiao, LM | 1 |
| Yang, DH | 1 |
| Xie, SF | 1 |
| Wang, YM | 1 |
| Zhao, NF | 2 |
| Li, MW | 1 |
| Lindh, M | 1 |
| Uhnoo, I | 1 |
| Bläckberg, J | 1 |
| Duberg, AS | 1 |
| Friman, S | 1 |
| Fischler, B | 1 |
| Karlström, O | 1 |
| Norkrans, G | 1 |
| Reichard, O | 1 |
| Sangfeldt, P | 1 |
| Söderström, A | 1 |
| Sönnerborg, A | 1 |
| Weiland, O | 2 |
| Wejstål, R | 1 |
| Wiström, J | 1 |
| Parvaz, P | 1 |
| Zarski, JP | 2 |
| Beaugrand, M | 1 |
| Benhamou, Y | 2 |
| Bailly, F | 1 |
| Maynard, M | 1 |
| Trepo, C | 1 |
| Trylesinski, A | 1 |
| Monchecourt, F | 1 |
| Choi, JW | 1 |
| Kim, TN | 1 |
| Eun, JR | 1 |
| Katsounas, A | 1 |
| Jochum, C | 1 |
| Canbay, A | 1 |
| Schlaak, J | 1 |
| Gerlich, WH | 1 |
| Gerken, G | 1 |
| Calleja, JL | 1 |
| Peñas, B | 1 |
| Poynard, T | 1 |
| Ngo, Y | 1 |
| Hadziyannis, S | 1 |
| Ratziu, V | 1 |
| Chien, RN | 2 |
| Liaw, YF | 2 |
| Tuma, P | 2 |
| Stornaiuolo, G | 1 |
| Brancaccio, G | 1 |
| Precone, V | 1 |
| Sgrò, G | 1 |
| Nardiello, S | 1 |
| Gaeta, GB | 2 |
| Elefsiniotis, I | 1 |
| Jardi, R | 1 |
| Vezali, E | 1 |
| Esteban, R | 1 |
| Fernández, JV | 1 |
| Medrano, J | 1 |
| Gong, ZJ | 2 |
| Hu, DF | 2 |
| Gervain, J | 1 |
| Horváth, G | 1 |
| Hunyady, B | 1 |
| Makara, M | 1 |
| Pár, A | 1 |
| Szalay, F | 1 |
| Tornai, I | 1 |
| Telegdy, L | 1 |
| Ahn, SY | 1 |
| Jang, YM | 1 |
| Choi, YH | 1 |
| Boyd, A | 1 |
| Lasnier, E | 1 |
| Molina, JM | 1 |
| Lascoux-Combe, C | 1 |
| Bonnard, P | 1 |
| Miailhes, P | 1 |
| Wendum, D | 1 |
| Meynard, JL | 1 |
| Girard, PM | 1 |
| Lacombe, K | 1 |
| Marzano, A | 3 |
| Marengo, A | 1 |
| Andreone, P | 1 |
| Volpes, R | 1 |
| Canova, D | 1 |
| Cursaro, C | 1 |
| Riili, A | 1 |
| Fiorentino, B | 1 |
| Bacci, M | 1 |
| Guazzini, S | 1 |
| Burra, P | 1 |
| Carosi, G | 1 |
| Rizzetto, M | 4 |
| Alberti, A | 1 |
| Cariti, G | 1 |
| Filice, G | 1 |
| Levrero, M | 1 |
| Mazzotta, F | 1 |
| Pastore, G | 1 |
| Piccinino, F | 1 |
| Prati, D | 1 |
| Raimondo, G | 1 |
| Sagnelli, E | 1 |
| Toti, M | 1 |
| Brunetto, M | 1 |
| Bruno, R | 1 |
| Di Marco, V | 1 |
| Ferrari, C | 1 |
| Pollicino, T | 1 |
| Puoti, M | 1 |
| Santantonio, T | 1 |
| Smedile, A | 1 |
| Pradeep Kumar, S | 1 |
| Medhi, S | 1 |
| Asim, M | 1 |
| Das, BC | 1 |
| Gondal, R | 1 |
| Kar, P | 1 |
| Andersen, ES | 1 |
| Leutscher, P | 1 |
| Krarup, H | 1 |
| Westin, J | 1 |
| Moessner, B | 1 |
| Konopski, Z | 1 |
| Frigstad, SO | 1 |
| Kjær, M | 1 |
| Christensen, PB | 1 |
| Weis, N | 1 |
| Wong, GL | 1 |
| Wong, VW | 1 |
| Choi, PC | 1 |
| Chan, AW | 1 |
| Chim, AM | 1 |
| Yiu, KK | 1 |
| Chu, SH | 1 |
| Chan, FK | 1 |
| Sung, JJ | 1 |
| Chan, HL | 1 |
| Mo, GS | 1 |
| Wu, ZL | 1 |
| Zhang, JL | 1 |
| Hhang, ZG | 1 |
| Cai, JG | 1 |
| Jie, ZH | 1 |
| Wu, XG | 1 |
| Shi, JP | 1 |
| Montagnani, M | 1 |
| Giandinoto, M | 1 |
| Lisotti, A | 1 |
| Galli, S | 1 |
| Azzaroli, F | 1 |
| Buonfiglioli, F | 1 |
| Turco, L | 1 |
| Aldini, R | 1 |
| Mazzella, G | 1 |
| Lim, SG | 3 |
| Aung, MO | 1 |
| Mak, B | 1 |
| Sutedja, D | 1 |
| Lee, YM | 1 |
| Lee, GH | 1 |
| Fernandes, M | 1 |
| Low, HC | 1 |
| Lai, V | 1 |
| Dan, YY | 1 |
| Sherman, M | 1 |
| Ebinuma, H | 1 |
| Saito, H | 1 |
| Singal, AK | 1 |
| Fontana, RJ | 2 |
| Tujios, SR | 1 |
| Lee, WM | 1 |
| Naggie, S | 1 |
| Sulkowski, MS | 1 |
| Chang, Y | 1 |
| Psevdos, G | 1 |
| Sharp, V | 1 |
| Köklü, S | 1 |
| Tuna, Y | 1 |
| Gülşen, MT | 1 |
| Demir, M | 1 |
| Köksal, AŞ | 1 |
| Koçkar, MC | 1 |
| Aygün, C | 1 |
| Coban, S | 1 |
| Ozdil, K | 1 |
| Ataseven, H | 2 |
| Akin, E | 1 |
| Pürnak, T | 1 |
| Yüksel, I | 1 |
| Ibiş, M | 1 |
| Yildirim, B | 1 |
| Nadir, I | 1 |
| Küçükazman, M | 1 |
| Akbal, E | 1 |
| Yüksel, O | 1 |
| Başar, O | 1 |
| Alkan, E | 1 |
| Baykal, O | 1 |
| Hulstaert, F | 1 |
| Schwierz, C | 1 |
| Nevens, F | 1 |
| Thiry, N | 1 |
| Gamil, M | 1 |
| Colle, I | 1 |
| Van de Sande, S | 1 |
| Horsmans, Y | 1 |
| Ristig, MB | 1 |
| Crippin, J | 2 |
| Aberg, JA | 1 |
| Powderly, WG | 1 |
| Lisker-Melman, M | 2 |
| Kessels, L | 1 |
| Tebas, P | 2 |
| Tillmann, HL | 2 |
| Bock, CT | 1 |
| Bleck, JS | 1 |
| Rosenau, J | 1 |
| Böker, KH | 1 |
| Barg-Hock, H | 1 |
| Becker, T | 1 |
| Trautwein, C | 3 |
| Klempnauer, J | 2 |
| Flemming, P | 2 |
| Manns, MP | 2 |
| Hadziyannis, SJ | 3 |
| Papatheodoridis, GV | 1 |
| Vassilopoulos, D | 1 |
| LOVGREN, O | 1 |
| LECOQ, R | 1 |
| HURT, GA | 1 |
| CHANUTIN, A | 1 |
| Maier, KP | 1 |
| Ristig, M | 1 |
| Drechsler, H | 1 |
| Chevillard, C | 1 |
| Moukoko, CE | 1 |
| Elwali, NE | 1 |
| Bream, JH | 1 |
| Kouriba, B | 1 |
| Argiro, L | 1 |
| Rahoud, S | 1 |
| Mergani, A | 1 |
| Henri, S | 1 |
| Gaudart, J | 1 |
| Mohamed-Ali, Q | 1 |
| Young, HA | 1 |
| Dessein, AJ | 1 |
| Perrillo, RP | 1 |
| Wiegand, J | 1 |
| Tischendorf, JJ | 1 |
| Nashan, B | 1 |
| Niemann, P | 1 |
| Rohde, P | 1 |
| Lo, CM | 1 |
| Cheung, ST | 1 |
| Ng, IO | 1 |
| Liu, CL | 1 |
| Lai, CL | 1 |
| Fan, ST | 1 |
| Sumida, Y | 1 |
| Kanemasa, K | 1 |
| Tachibana, S | 1 |
| Maekawa, K | 1 |
| Mori, K | 2 |
| Minami, M | 1 |
| Okanoue, T | 1 |
| Lai, CJ | 1 |
| Terrault, NA | 1 |
| Neff, GW | 1 |
| Nery, J | 1 |
| Lau, DT | 1 |
| O'Brien, CB | 1 |
| Duncan, R | 1 |
| Shire, NJ | 1 |
| Ruiz, P | 1 |
| Nery, C | 1 |
| Montalbano, M | 1 |
| Muslu, H | 1 |
| Safdar, K | 1 |
| Schiff, ER | 1 |
| Tzakis, AG | 1 |
| Madariaga, JR | 1 |
| Mazzaferro, V | 1 |
| Carenzi, S | 1 |
| Romito, R | 1 |
| Pulvirenti, A | 1 |
| Franchello, A | 1 |
| Salizzoni, M | 1 |
| Taltavull, TC | 1 |
| Chahri, N | 1 |
| Verdura, B | 1 |
| Gornals, J | 1 |
| Lopez, C | 1 |
| Casanova, A | 1 |
| Cañas, C | 1 |
| Figueras, J | 1 |
| Casais, LA | 1 |
| Moon, W | 1 |
| Choi, MS | 1 |
| Moon, YM | 1 |
| Koh, KC | 1 |
| Yoo, BC | 1 |
| Rhee, JC | 1 |
| Shim, SG | 1 |
| Tseng, PL | 1 |
| Lu, SN | 1 |
| Tung, HD | 1 |
| Wang, JH | 1 |
| Changchien, CS | 1 |
| Lee, CM | 2 |
| Tassopoulos, NC | 2 |
| Heathcote, EJ | 2 |
| Chang, TT | 2 |
| Kitis, G | 2 |
| Goodman, Z | 2 |
| Ma, J | 2 |
| Arterburn, S | 2 |
| Xiong, S | 1 |
| Currie, G | 1 |
| Brosgart, CL | 2 |
| Su, GG | 1 |
| Ying, MF | 1 |
| Kim, KM | 1 |
| Choi, WB | 1 |
| Lee, HC | 1 |
| Chung, YH | 1 |
| Lee, YS | 1 |
| Spiering, W | 1 |
| Kroon, AA | 1 |
| de Leeuw, PW | 1 |
| Yeh, CT | 1 |
| Grattagliano, I | 1 |
| Palmieri, VO | 1 |
| Portincasa, P | 1 |
| Palasciano, G | 1 |
| Blaas, S | 1 |
| Schneidewind, A | 1 |
| Glück, T | 1 |
| Salzberger, B | 1 |
| Borroto-Esoda, K | 1 |
| Chuck, SL | 1 |
| Takamura, M | 1 |
| Ichida, T | 1 |
| Ohkoshi, S | 1 |
| Tsubata, S | 1 |
| Osaki, A | 1 |
| Aoyagi, T | 1 |
| Nomoto, M | 1 |
| Uehara, K | 1 |
| Terada, H | 1 |
| Aoyagi, Y | 1 |
| Ranneberg, B | 1 |
| Mertenskoetter, T | 1 |
| Pearce, G | 1 |
| Widjaja, D | 1 |
| Yarlagadda, S | 1 |
| Singu, BS | 1 |
| Loganathan, RS | 1 |
| Blum, S | 1 |
| Bloom, A | 1 |
| Remy, P | 1 |
| Mallet, VO | 1 |
| Dhalluin-Venier, V | 1 |
| Verkarre, V | 1 |
| Correas, JM | 1 |
| Chaix, ML | 1 |
| Viard, JP | 1 |
| Pol, S | 1 |
| Matthews, GV | 1 |
| Cooper, DA | 1 |
| Dore, GJ | 1 |
| Arora, G | 1 |
| Keeffe, EB | 2 |
| Yeon, JE | 1 |
| Byun, KS | 1 |
| Kim, GH | 1 |
| Faria, LC | 1 |
| Gigou, M | 1 |
| Roque-Afonso, AM | 1 |
| Sebagh, M | 1 |
| Fallot, G | 1 |
| Ferrari, TC | 1 |
| Guettier, C | 1 |
| Dussaix, E | 1 |
| Castaing, D | 1 |
| Brechot, C | 1 |
| Ayoub, WS | 1 |
| Bjersing, L | 1 |
| Andersson, C | 1 |
| Lithner, F | 1 |
| Zaima, M | 1 |
| Noguchi, M | 1 |
| Wada, Y | 1 |
| Ozawa, K | 1 |
| Ho, Y | 1 |
| Lin, HJ | 1 |
| Mirvish, SS | 1 |
| Medalie, J | 1 |
| Linsell, CA | 1 |
| Yousuf, E | 1 |
| Reyad, S | 1 |
| Bielik, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)[NCT04724785] | 10,000 participants (Anticipated) | Observational | 2020-12-01 | Recruiting | |||
| A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B[NCT00117676] | Phase 3 | 382 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B[NCT00116805] | Phase 3 | 266 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial[NCT00663182] | Phase 4 | 200 participants (Anticipated) | Interventional | 2008-01-31 | Enrolling by invitation | ||
| HBV Viral Suppression by Entecavir in Adefovir Partial Responders[NCT00704106] | 60 participants (Actual) | Observational | 2008-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 76.3 |
| ADV-TDF | 77.1 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 72.4 |
| ADV-TDF | 68.5 |
(NCT00117676)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 93.2 |
| ADV-TDF | 63.2 |
(NCT00117676)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 90.6 |
| ADV-TDF | 89.3 |
(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | units per liter (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -124.4 | -138.5 | -140.0 | -140.3 | -139.5 | -134.7 | -143.1 | -132.6 | -131.9 | -129.2 |
| TDF-TDF | -95.0 | -93.7 | -99.1 | -99.6 | -97.7 | -98.9 | -98.9 | -96.1 | -97.0 | -94.9 |
(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 copies/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -4.07 | -4.74 | -4.77 | -4.75 | -4.77 | -4.81 | -4.81 | -4.79 | -4.69 | -4.75 |
| TDF-TDF | -4.57 | -4.54 | -4.61 | -4.56 | -4.59 | -4.61 | -4.61 | -4.56 | -4.60 | -4.57 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 240
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Score | Ishak Score | |
| ADV-TDF | -4.9 | -4.2 |
| TDF-TDF | -4.6 | -4.0 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Necroinflammatory Score | Ishak Necroinflammatory Score | |
| ADV-TDF | -3.4 | -2.6 |
| TDF-TDF | -3.5 | -2.6 |
(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | units per liter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -0.6 | -0.3 | -3.6 | -3.9 | -4.1 | -2.0 | -3.9 | -8.9 | -5.9 |
| TDF-TDF | 2.4 | -0.6 | 0.7 | -2.5 | -3.9 | -2.6 | -2.9 | -4.6 | -2.8 |
(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 copies/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -0.60 | -0.63 | -0.61 | -0.61 | -0.64 | -0.65 | -0.66 | -0.67 | -0.72 |
| TDF-TDF | 0.02 | -0.03 | 0.01 | -0.04 | -0.04 | -0.05 | -0.02 | -0.04 | -0.05 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 97 to 144
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 4 | 0 | 1 | 2 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 145 to 192
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 3 | 0 | 1 | 1 | 1 |
| TDF-TDF With Addition of FTC | 1 | 0 | 0 | 1 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 193 to 240
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 2 | 0 | 0 | 0 | 2 |
| TDF-TDF | 1 | 1 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 2 | 0 | 2 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 241 to 288
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF | 3 | 0 | 2 | 1 | 0 |
| TDF-TDF With Addition of FTC | 1 | 0 | 1 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 289 to 336
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 1 | 0 | 0 | 1 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 337 to 384
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 385 to 432
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF | 2 | 0 | 0 | 2 | 0 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 48, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 42 | 7 | 14 | 20 | 1 |
| TDF-TDF | 8 | 0 | 3 | 4 | 1 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 433 to 480
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to genotype | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 49 to 96
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites within HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 6 | 0 | 2 | 4 | 0 |
| TDF-TDF With Addition of FTC | 1 | 0 | 1 | 0 | 0 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 70.0 | 76.4 | 75.7 | 72.9 | 65.4 | 69.2 |
| TDF-TDF | 74.3 | 68.2 | 70.3 | 69.9 | 65.9 | 65.3 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 87.2 | 88.9 |
| TDF-TDF | 86.5 | 80.0 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 96. (NCT00117676)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | Anti-HBs Seroconversion | |
| ADV-TDF | 0 | 0 |
| TDF-TDF | 0 | 0 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBsAg Loss - Week 144 | Anti-HBs Seroconversion - Week 144 | HBsAg Loss - Week 192 | Anti-HBs Seroconversion - Week 192 | HBsAg Loss - Week 240 | Anti-HBs Seroconversion - Week 240 | HBsAg Loss - Week 288 | Anti-HBs Seroconversion - Week 288 | HBsAg Loss - Week 336 | Anti-HBs Seroconversion - Week 336 | HBsAg Loss - Week 384 | Anti-HBs Seroconversion - Week 384 | HBsAg Loss - Week 432 | Anti-HBs Seroconversion - Week 432 | HBsAg Loss - Week 480 | Anti-HBs Seroconversion - Week 480 | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0.8 | 0 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 1.6 | 0.8 | 2.4 | 0.8 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.8 | 0.4 | 1.2 | 0.4 | 1.2 | 0.8 |
"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 48.8 | 51.2 |
| TDF-TDF | 70.8 | 29.2 |
(NCT00117676)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 88.4 | 86.8 | 83.9 | 82.9 | 78.0 | 76.3 |
| TDF-TDF | 86.7 | 84.0 | 82.8 | 80.5 | 77.0 | 74.3 |
(NCT00117676)
Timeframe: Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 97.7 | 100.0 |
| TDF-TDF | 97.6 | 100.0 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | Seroconversion to anti-HBs | |
| ADV-TDF | 0 | 0 |
| TDF-TDF | 0 | 0 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 85.1 | 14.9 |
| TDF-TDF | 87.3 | 12.7 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 68.8 | 31.2 |
| TDF-TDF | 72.4 | 27.6 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | |
| ADV-TDF | 94.6 | 1.4 | 4.1 | 59.5 | 33.8 | 6.8 |
| TDF-TDF | 96.7 | 2.7 | 0.7 | 62.0 | 34.0 | 4.0 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Missing Data - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | Missing Data - Fibrosis | |
| ADV-TDF | 81.6 | 8.0 | 0.8 | 9.6 | 25.6 | 54.4 | 10.4 | 9.6 |
| TDF-TDF | 82.0 | 6.8 | 4.8 | 6.4 | 22.0 | 63.2 | 8.4 | 6.4 |
ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 68.0 |
| ADV-TDF | 54.4 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 65.2 |
| ADV-TDF | 74.4 |
"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 66.5 |
| ADV 10 mg | 12.2 |
(NCT00116805)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 76.1 |
| ADV-TDF | 13.3 |
(NCT00116805)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TDF-TDF | 77.6 |
| ADV-TDF | 77.9 |
(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | U/L (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -106.1 | -120.4 | -126.2 | -139.6 | -134.8 | -130.9 | -132.3 | -133.7 | -162.1 | -157.5 |
| TDF-TDF | -107.2 | -107.8 | -100.7 | -101.4 | -95.9 | -102.3 | -101.9 | -108.1 | -105.0 | -92.3 |
(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 IU/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 48 | Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -3.93 | -6.38 | -6.31 | -6.49 | -6.45 | -6.49 | -6.46 | -6.28 | -6.45 | -6.37 |
| TDF-TDF | -6.17 | -6.26 | -6.32 | -6.30 | -6.22 | -6.27 | -6.35 | -6.38 | -6.13 | -6.18 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 240
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Necroinflammatory Score | Ishak Necroinflammatory Score | |
| ADV-TDF | -5.1 | -4.5 |
| TDF-TDF | -4.8 | -4.1 |
The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knodell Necroinflammatory Score | Ishak Necroinflammatory Score | |
| ADV-TDF | -3.2 | -2.6 |
| TDF-TDF | -3.6 | -2.7 |
(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | U/L (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -6.9 | -0.7 | -7.8 | -8.1 | -10.3 | -9.3 | -6.9 | -11.6 | -7.1 |
| TDF-TDF | -2.0 | -0.4 | -1.3 | 3.7 | -1.6 | -1.2 | -4.4 | -4.3 | -5.5 |
(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | log10 IU/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | Week 432 | Week 480 | |
| ADV-TDF | -2.43 | -2.27 | -2.41 | -2.49 | -2.62 | -2.59 | -2.34 | -2.32 | -2.16 |
| TDF-TDF | -0.10 | -0.19 | -0.20 | -0.14 | -0.18 | -0.25 | -0.29 | -0.13 | -0.24 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 97 to 144
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 5 | 2 | 3 | 0 | 0 |
| ADV-TDF With Addition of FTC | 5 | 0 | 0 | 3 | 1 |
| TDF-TDF | 2 | 1 | 0 | 1 | 0 |
| TDF-TDF With Addition of FTC | 7 | 2 | 3 | 2 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 145 to 192
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 1 | 0 | 1 | 0 | 0 |
| ADV-TDF With Addition of FTC | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF | 2 | 0 | 1 | 0 | 1 |
| TDF-TDF With Addition of FTC | 5 | 0 | 0 | 1 | 3 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 193 to 240
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| ADV-TDF With Addition of FTC | 1 | 1 | 0 | 0 | 0 |
| TDF-TDF | 3 | 0 | 2 | 1 | 0 |
| TDF-TDF With Addition of FTC | 3 | 0 | 0 | 2 | 1 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 241 to 288
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| ADV-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 3 | 0 | 0 | 2 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 289 to 336
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 1 | 0 | 0 | 1 | 0 |
| ADV-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 337 to 384
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 2 | 1 | 1 | 0 | 0 |
| ADV-TDF With Addition of FTC | 2 | 0 | 1 | 1 | 0 |
| TDF-TDF | 1 | 0 | 0 | 0 | 1 |
| TDF-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 385 to 432
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 0 | 0 | 0 | 0 | 0 |
| ADV-TDF With Addition of FTC | 1 | 0 | 0 | 1 | 0 |
| TDF-TDF | 1 | 0 | 1 | 0 | 0 |
| TDF-TDF With Addition of FTC | 3 | 0 | 0 | 3 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 75 | 8 | 17 | 43 | 7 |
| TDF-TDF | 31 | 2 | 13 | 7 | 9 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 433 to 480
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 1 | 0 | 0 | 1 | 0 |
| ADV-TDF With Addition of FTC | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF | 0 | 0 | 0 | 0 | 0 |
| TDF-TDF With Addition of FTC | 3 | 0 | 1 | 2 | 0 |
Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 49 to 96
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Participants evaluated | Changes at conserved sites in HBV polymerase | Changes at polymorphic sites in HBV polymerase | No genotypic changes (wild-type virus) | Unable to be genotyped | |
| ADV-TDF | 16 | 2 | 1 | 12 | 1 |
| ADV-TDF With Addition of FTC | 10 | 3 | 2 | 3 | 2 |
| TDF-TDF | 18 | 2 | 3 | 10 | 3 |
| TDF-TDF With Addition of FTC | 13 | 0 | 1 | 5 | 7 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 67.8 | 69.4 | 65.9 | 70.1 | 67.9 | 67.1 |
| TDF-TDF | 60.2 | 59.6 | 50.0 | 51.3 | 46.2 | 52.6 |
ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 78.6 | 82.8 |
| TDF-TDF | 79.6 | 75.0 |
HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 96. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 96. (NCT00116805)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | Seroconversion to Anti-HBe | |
| ADV-TDF | 25.6 | 22.0 |
| TDF-TDF | 25.9 | 22.8 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | Anti-HBs Seroconversion | |
| ADV-TDF | 5.8 | 4.7 |
| TDF-TDF | 5.3 | 4.1 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480
| Intervention | percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBsAg Loss - Week 144 | Anti-HBs Seroconversion - Week 144 | HBsAg Loss - Week 192 | Anti-HBs Seroconversion - Week 192 | HBsAg Loss - Week 240 | Anti-HBs Seroconversion - Week 240 | HBsAg Loss - Week 288 | Anti-HBs Seroconversion - Week 288 | HBsAg Loss - Week 336 | Anti-HBs Seroconversion - Week 336 | HBsAg Loss - Week 384 | Anti-HBs Seroconversion - Week 384 | HBsAg Loss - Week 432 | Anti-HBs Seroconversion - Week 432 | HBsAg Loss - Week 480 | Anti-HBs Seroconversion - Week 480 | |
| ADV-TDF | 8.0 | 6.8 | 7.9 | 6.7 | 8.0 | 8.0 | 8.0 | 8.0 | 7.9 | 7.9 | 9.0 | 7.9 | 10.2 | 8.0 | 10.1 | 7.9 |
| TDF-TDF | 7.5 | 5.2 | 9.4 | 6.4 | 9.2 | 6.3 | 9.2 | 6.4 | 10.3 | 7.5 | 11.0 | 8.1 | 10.9 | 7.6 | 10.9 | 8.0 |
(NCT00116805)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 144 | Week 192 | Week 240 | Week 288 | Week 336 | Week 384 | |
| ADV-TDF | 70.5 | 71.6 | 66.3 | 64.8 | 62.1 | 60.5 |
| TDF-TDF | 71.7 | 67.9 | 63.4 | 61.3 | 59.4 | 56.1 |
(NCT00116805)
Timeframe: Weeks 432 and 480
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 432 | Week 480 | |
| ADV-TDF | 100.0 | 96.6 |
| TDF-TDF | 93.0 | 98.0 |
HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 48. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBeAg Loss | HBeAg Seroconversion | |
| ADV-TDF | 17.5 | 17.5 |
| TDF-TDF | 22.2 | 20.9 |
HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| HBsAg Loss | HBsAg Seroconversion | |
| ADV-TDF | 0 | 0 |
| TDF-TDF | 3.2 | 1.3 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 89.6 | 10.4 |
| TDF-TDF | 88.2 | 11.8 |
Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Yes | No | |
| ADV-TDF | 67.8 | 32.2 |
| TDF-TDF | 74.4 | 25.6 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 240
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | |
| ADV-TDF | 97.9 | 2.1 | 0 | 58.3 | 39.6 | 2.1 |
| TDF-TDF | 96.1 | 3.9 | 0 | 56.6 | 39.5 | 3.9 |
Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 48
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Improvement - Necroinflammation | No Change - Necroinflammation | Worsening - Necroinflammation | Missing Data - Necroinflammation | Improvement - Fibrosis | No Change - Fibrosis | Worsening - Fibrosis | Missing Data - Fibrosis | |
| ADV-TDF | 78.9 | 3.3 | 5.6 | 12.2 | 20.0 | 61.1 | 6.7 | 12.2 |
| TDF-TDF | 81.3 | 4.5 | 3.4 | 10.8 | 19.9 | 63.6 | 5.1 | 11.4 |
29 reviews available for adenine and Liver Cirrhosis
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Hepatitis Delta: Prevalence, Natural History, and Treatment Options.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Global Health; | 2020 |
Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; | 2014 |
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepat | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis | 2014 |
An update on hepatitis B, D, and E viruses.
Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic | 2014 |
Prevention of hepatitis B virus reinfection in liver transplant recipients.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Liver; | 2014 |
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence.
Topics: Adenine; Antiviral Agents; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Im | 2015 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtr | 2008 |
[Entecavir].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug T | 2008 |
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Admi | 2008 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug | 2008 |
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Human | 2011 |
[Prevention for the development of hepatitis B virus-related hepatocellular carcinoma by anti-viral treatment].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lam | 2011 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease | 2012 |
Treatment of HBeAg-negative chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Endpoint Determination; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum | 2003 |
Management of patients with decompensated HBV cirrhosis.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance; Hepatiti | 2003 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S | 2003 |
Management of the patient with hepatitis B virus-related cirrhosis.
Topics: Adenine; Antiviral Agents; Hepatitis B; Humans; Interferons; Lamivudine; Liver Cirrhosis; Nucleoside | 2003 |
Management of hepatitis B in liver transplantation patients.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lam | 2004 |
Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhos | 2004 |
[Liver transplantation for complications of hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combinati | 2006 |
[Therapy of hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Drug Antagonism; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Co | 2006 |
[Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep | 2006 |
Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
Topics: Adenine; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatit | 2007 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtrici | 2008 |
29 trials available for adenine and Liver Cirrhosis
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens | 2017 |
Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance.
Topics: Adenine; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Creat | 2017 |
Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Chi-Square Distribution; China; | 2013 |
De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
Topics: Adenine; Adult; Alanine Transaminase; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square | 2013 |
Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; | 2014 |
Curative effect of combined lamivudine, adefovir dipivoxil, and stem cell transplantation on decompensated hepatitis B cirrhosis.
Topics: Adenine; alpha-Fetoproteins; Cholinesterases; Combined Modality Therapy; Female; Hepatitis B virus; | 2014 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I | 2015 |
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatiti | 2015 |
[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].
Topics: Adenine; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferas | 2015 |
Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B virus; Hepatit | 2016 |
[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; DNA, Viral; | 2016 |
Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; L | 2017 |
[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Female; Glomerulonephritis; Hepatitis B; Hepatitis B v | 2008 |
[Lamivudine and adefovir dipivoxil combination treatment for liver cirrhosis patients with CHB].
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; | 2008 |
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Biopsy; Double-Blind Method; Female; Hepatitis B e Ant | 2009 |
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Collagen; DNA, Viral; Drug Resistance, | 2009 |
Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B | 2011 |
[One-year combination therapy de novo of adefovir dipivoxil and lamivudine for decompensated cirrhosis related to HBV].
Topics: Adenine; Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Hepatitis B virus; Human | 2011 |
Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
Topics: Adenine; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Fem | 2011 |
[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B].
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; | 2012 |
[Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepati | 2012 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; H | 2002 |
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatic Encephalopathy; Hepa | 2005 |
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Animals; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Adminis | 2005 |
Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Drug Combinations; Drug Resistance, V | 2005 |
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; | 2006 |
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis, Chronic; Humans; | 2007 |
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Circular; DNA, V | 2008 |
79 other studies available for adenine and Liver Cirrhosis
| Article | Year |
|---|---|
Differentiation-inducing factor-1 prevents hepatic stellate cell activation through inhibiting GSK3β inactivation.
Topics: Active Transport, Cell Nucleus; Adenine; Animals; Antineoplastic Agents; beta Catenin; Cell Differen | 2019 |
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therap | 2017 |
Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?
Topics: Adenine; Humans; Liver Cirrhosis; Organophosphonates; Tenofovir | 2017 |
Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis B | 2017 |
Trolline Ameliorates Liver Fibrosis by Inhibiting the NF-κB Pathway, Promoting HSC Apoptosis and Suppressing Autophagy.
Topics: Adenine; Alkaloids; Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; bcl-2-Associated X P | 2017 |
Chronic hepatitis B virus and liver fibrosis: A mathematical model.
Topics: Adenine; Computer Simulation; Diffusion; Drug Delivery Systems; Hepatic Stellate Cells; Hepatitis B | 2018 |
β-Arrestin1 enhances liver fibrosis through autophagy-mediated Snail signaling.
Topics: Adenine; Animals; Autophagy; beta-Arrestin 1; Cell Line; Female; Glycogen Synthase Kinase 3 beta; He | 2019 |
Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Management; DNA, Viral; Fema | 2019 |
Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; China; Female; Guanine; Hepatitis | 2019 |
Fibrosing Cholestatic Hepatitis-Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B.
Topics: Adenine; Biopsy, Needle; Cholestasis; Disease Progression; Follow-Up Studies; Hepatitis B, Chronic; | 2019 |
Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surf | 2019 |
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administrat | 2013 |
[Treatment of one advanced schistosomiasis patient with hepatitis B cirrhosis by lamivudine and adefovir dipivoxil].
Topics: Adenine; Adult; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Sc | 2013 |
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective.
Topics: Adenine; Adult; Aged; Bilirubin; Creatinine; DNA, Viral; Female; Hepatitis B, Chronic; Humans; India | 2013 |
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedul | 2013 |
Expression and function of methylthioadenosine phosphorylase in chronic liver disease.
Topics: Adenine; Animals; Apoptosis; Chronic Disease; Gene Expression Regulation; Hepatic Stellate Cells; He | 2013 |
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
Topics: Adenine; Adult; Cohort Studies; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Guanine; | 2014 |
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; | 2014 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Gu | 2014 |
Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Mal | 2014 |
Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Hepatitis B, Chronic; Humans; I | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e | 2014 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA | 2014 |
Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; China; DNA, Viral; Drug Resistance, Viral; Drug Therap | 2015 |
Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Ima | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanin | 2016 |
Naringin in Ganshuang Granule suppresses activation of hepatic stellate cells for anti-fibrosis effect by inhibition of mammalian target of rapamycin.
Topics: Adenine; Animals; Autophagy; Cells, Cultured; Drugs, Chinese Herbal; Fibrosis; Flavanones; Hepatic S | 2017 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepat | 2018 |
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; | 2017 |
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Cohort Studies; Drug Resistance; Female; Genotype; Hepat | 2009 |
[A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus].
Topics: Absorptiometry, Photon; Adenine; Adult; Antiviral Agents; Bone Density; DNA, Viral; Drug Resistance, | 2008 |
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus; | 2008 |
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hep | 2009 |
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan | 2009 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface | 2010 |
[A case of osteomalacia related to adefovir in a patient with chronic hepatitis B].
Topics: Adenine; Aged; Alkaline Phosphatase; Antiviral Agents; Dietary Supplements; DNA, Viral; Hepatitis B, | 2010 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort | 2010 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B | 2010 |
Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B; Hepatitis | 2010 |
Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs.
Topics: Adenine; Adult; Elasticity Imaging Techniques; Female; Hepatitis B; Humans; Lamivudine; Liver; Liver | 2011 |
On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Progression; Elasticit | 2011 |
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Huma | 2012 |
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis | 2011 |
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infec | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, | 2013 |
Should chronic hepatitis B be treated as early as possible?
Topics: Adenine; Adult; Antiviral Agents; Belgium; Cost-Benefit Analysis; Early Diagnosis; Guanine; Health C | 2013 |
Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.
Topics: Adenine; Adult; Antiviral Agents; Bacterial Infections; Cholestasis; Drug Resistance, Microbial; Fib | 2003 |
The concentration of adenine in red blood cells in cirrhosis of liver.
Topics: Adenine; Erythrocytes; Humans; Liver Cirrhosis | 1954 |
[Adenine deficiency in the grave manifestations of chronic alcoholism].
Topics: Adenine; Alcoholism; Humans; Liver Cirrhosis; Mental Disorders; Psychoses, Alcoholic; Psychotic Diso | 1955 |
ORGANIC PHOSPHATE COMPOUNDS OF ERYTHROCYTES FROM INDIVIDUALS WITH CIRRHOSIS OF THE LIVER.
Topics: Adenine; Erythrocytes; Glycerophosphates; Hexosephosphates; Humans; Liver Cirrhosis; Nucleosides; Nu | 1965 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B viru | 2003 |
IFN-gamma polymorphisms (IFN-gamma +2109 and IFN-gamma +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni).
Topics: Adenine; DNA; Genetic Predisposition to Disease; Genotype; Guanine; Humans; Interferon-gamma; Liver | 2003 |
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hep | 2004 |
Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin.
Topics: Adenine; Adult; Antiviral Agents; Cholestasis, Intrahepatic; Drug Resistance, Viral; Drug Therapy, C | 2004 |
[A case of liver cirrhosis B resistant to lamivudine showing the clinical effect of adefovir dipivoxil].
Topics: Adenine; Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hep | 2004 |
Tenofovir therapy for lamivudine resistance following liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B, | 2004 |
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Topics: Adenine; Adult; Antibodies, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Ant | 2005 |
Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hep | 2005 |
[Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease].
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Humans; Lamivud | 2005 |
[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation].
Topics: Adenine; Adult; Aged; Amino Acid Motifs; Antiviral Agents; DNA-Directed DNA Polymerase; Female; Hepa | 2005 |
A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
Topics: Adenine; Alleles; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cytosine; Heart | 2005 |
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resistance | 2006 |
Adefovir dipivoxyl for the treatment of delta-related liver cirrhosis.
Topics: Adenine; Female; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Liver Cirrhosis; Middle Aged; | 2006 |
Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases.
Topics: Acute Kidney Injury; Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; H | 2006 |
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resis | 2007 |
Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.
Topics: Acute Kidney Injury; Adenine; HIV Infections; Humans; Liver Cirrhosis; Organophosphonates; Reverse T | 2007 |
Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.
Topics: Adenine; Adolescent; Adult; Black or African American; Contraindications; Female; Hepatitis B, Chron | 2007 |
Reversibility of cirrhosis in HIV/HBV coinfection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, V | 2007 |
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Topics: Adenine; CD4 Lymphocyte Count; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; H | 2007 |
[New German and American guidelines for therapy of hepatitis B. Discrepancies and similarities].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th | 2007 |
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigen | 2008 |
Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations.
Topics: Adenine; Aged; Aged, 80 and over; Alleles; Base Sequence; Carcinoma, Hepatocellular; Cell Division; | 1996 |
Sequential decrease in platelet energy charge after hepatic resection in cirrhotics.
Topics: Adenine; Adenosine Triphosphate; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blood Platelet | 1990 |
Patterns of excretion of methylated purines in hepatocellular carcinoma.
Topics: Adenine; Adult; Carcinoma, Hepatocellular; Chromatography, Paper; Creatine; Guanine; Humans; Hydroly | 1974 |
7-methylguanine and other minor urinary purines: values for normal subjects from Israel, Gaza, and Kenya, and for patients with cancer of various organs or cirrhosis of the liver.
Topics: Adenine; Adult; Aged; Arabia; Child; Creatinine; Female; Humans; Hypoxanthines; Israel; Kenya; Liver | 1971 |
[Dihydroxyacetone metabolism in blood hemolysates of subjects with liver cirrhosis].
Topics: Acetone; Adenine; Adenosine Triphosphate; Erythrocytes; Hemolysis; Humans; Liver Cirrhosis; Nucleosi | 1967 |